Search Results

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 45,525 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company.

Ultragenyx Pharmaceutical Inc. announced that it has commenced an underwritten public offering of up to $350,000,000 of shares of its common stock and, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, announced the pricing of its underwritten public offering of 7,435,898 shares of its common stock at a price to the public of $39.00 per share.

Ultragenyx Pharmaceutical Inc. reported the grant of 17,180 restricted stock units of the company’s common stock to ten newly hired non-executive officers of the company.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that Eric Crombez, M.D., the company’s chief medical officer and executive vice president, will participate in a fireside at Bank of America’s 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company’s chief executive officer, will participate in a fireside at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 10:00 a.m. ET.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended March 31, 2024 and reaffirmed its financial guidance for 2024.

Ultragenyx Pharmaceutical Inc. announced that the company held a successful meeting with the U.S. Food and Drug Administration during which the company reached agreement with the Agency that cerebral spinal fluid heparan sulfate is a reasonable surrogate endpoint that could support submission of a biologics license application seeking accelerated approval for UX111 AAV gene therapy for the treatment of Sanfilippo syndrome.